Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

637
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
637
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

696
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
696

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ring-Electrode AC Plasmonic Nanopore Sensing for DNA Load Characterization of Single Adeno-Associated Viruses.

Sensors (Basel, Switzerland)·2026
Same author

rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusion.

Frontiers in medicine·2026
Same author

Progress and challenges in intrathecal gene therapy for neurological disorders.

EBioMedicine·2026
Same author

Plasmonic Nanopore Sensing to Probe the DNA Loading Status of Adeno-Associated Viruses.

Chemosensors (Basel, Switzerland)·2026
Same author

Correction: Vyas et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 14611.

International journal of molecular sciences·2026
Same author

Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

miR-19a-3p and miR-19b-3p Promote Microglia Activation Associated With Neuroinflammation.

Journal of neuroscience research·2026
Same journal

Correction to "Chronic Nicotine and Smoke Treatment Modulate Dopaminergic Activities in Ventral Tegmental Area and Nucleus Accumbens and the γ-Aminobutyric Acid Type B Receptor Expression of the Rat Prefrontal Cortex".

Journal of neuroscience research·2026
Same journal

EXPRESSION OF CONCERN: Hypoxia-Induced Deactivation of NGF-Mediated ERK1/2 Signaling in Hippocampal Cells: Neuroprotection by Acetyl-L-Carnitine.

Journal of neuroscience research·2026
Same journal

DKK1 Targeting in Corneal Schwann Cells Rescues Axonal Regeneration and Mechanosensory Function After Corneal Injury.

Journal of neuroscience research·2026
Same journal

An Examination of Task-Evoked fMRI Data Processing in Functional Connectivity.

Journal of neuroscience research·2026
Same journal

Association of Interhemispheric Structural Integrity With Transcallosal Interhemispheric Inhibition in People With Chronic Stroke.

Journal of neuroscience research·2026
See all related articles

Related Experiment Video

Updated: Mar 15, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K

Immunological considerations for treating globoid cell leukodystrophy.

Subha Karumuthil-Melethil1, Steven J Gray2,3

  • 1Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.

Journal of Neuroscience Research
|September 18, 2016
PubMed
Summary
This summary is machine-generated.

Globoid cell leukodystrophy (GLD), a severe inherited neurodegenerative disease, involves inflammation and immune responses. This review explores their role in GLD progression and treatment strategies, offering insights for related conditions.

Keywords:
GALCKrabbe's diseasegloboid cell leukodystrophyimmuneneuroinflammationpsychosine

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Mar 15, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.5K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Globoid cell leukodystrophy (GLD), also known as Krabbe's disease, is a severe inherited neurodegenerative disorder resulting from GALC enzyme deficiency.
  • GLD affects humans and animal models (murine, canine, nonhuman primate), presenting challenges in understanding its pathogenesis.
  • Current therapeutic strategies for GLD, including enzyme replacement, gene therapy, and bone marrow transplant, have not yielded complete efficacy.

Purpose of the Study:

  • To review the role of inflammation and immune responses in the progression of Globoid cell leukodystrophy (GLD).
  • To examine the interplay between various GLD treatment strategies and the innate and adaptive immune responses.
  • To discuss the potential relevance of these concepts to other related diseases.

Main Methods:

  • Literature review of existing research on Globoid cell leukodystrophy (GLD).
  • Analysis of the involvement of neuroinflammation and immune system components in GLD pathogenesis.
  • Evaluation of how different therapeutic interventions interact with immune responses in GLD.

Main Results:

  • Neuroinflammation is a key component in GLD progression, potentially preceding demyelination and overt symptoms.
  • The effectiveness of current GLD treatments is limited, partly due to a lack of full understanding of immune system involvement.
  • Understanding the immune response in GLD is crucial for developing more effective therapeutic approaches.

Conclusions:

  • Inflammation and immune responses play a significant role in the pathogenesis and progression of Globoid cell leukodystrophy (GLD).
  • Further research into the interplay between GLD and the immune system is essential for advancing treatment strategies.
  • The findings have implications for understanding and treating other related neurodegenerative and lysosomal storage diseases.